180 related articles for article (PubMed ID: 8898435)
1. Economic evaluation in gastrointestinal disease.
Jönsson B; Karlsson G
Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Jönsson B
Scand J Gastroenterol Suppl; 1996; 215():90-5. PubMed ID: 8722390
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Barradell LB; McTavish D
Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
[TBL] [Abstract][Full Text] [Related]
4. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
Craig AM; Davey P; Malek M; Murray F
Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472
[TBL] [Abstract][Full Text] [Related]
6. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Duggan AE; Tolley K; Hawkey CJ; Logan RF
BMJ; 1998 May; 316(7145):1648-54. PubMed ID: 9603748
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
O'Brien B; Goeree R; Mohamed AH; Hunt R
Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
[TBL] [Abstract][Full Text] [Related]
8. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
Unge P; Jönsson B; Stålhammar NO
Pharmacoeconomics; 1995 Nov; 8(5):410-27. PubMed ID: 10160075
[TBL] [Abstract][Full Text] [Related]
9. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
Frampton JE; McTavish D
Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
[TBL] [Abstract][Full Text] [Related]
10. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
[TBL] [Abstract][Full Text] [Related]
11. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
Adamek RJ; Behrendt J; Wenzel C
Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):811-7. PubMed ID: 11474311
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
Wilde MI; McTavish D
Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
[TBL] [Abstract][Full Text] [Related]
13. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study.
Saberi-Firoozi M; Massarrat S; Zare S; Fattahi M; Javan A; Etaati H; Dehbashi N
Am J Gastroenterol; 1995 Sep; 90(9):1419-23. PubMed ID: 7661161
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer.
O'Brien B; Goeree R; Hunt R; Wilkinson J; Levine M; William A
Can J Gastroenterol; 1997; 11(4):323-31. PubMed ID: 9218858
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Vakil N; Fennerty MB
Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of new medical technology.
Jönsson B
Scand J Gastroenterol Suppl; 1994; 201():87-90. PubMed ID: 8047831
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
18. Effect of omeprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the healing of duodenal ulcer: comparison with a historical control.
Schütze K; Hentschel E; Hirschl AM
Hepatogastroenterology; 1999; 46(28):2358-62. PubMed ID: 10521998
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
